DE602008004469D1 - Kombination zur verwendung bei der behandlung von entzündlichen erkrankungen - Google Patents

Kombination zur verwendung bei der behandlung von entzündlichen erkrankungen

Info

Publication number
DE602008004469D1
DE602008004469D1 DE602008004469T DE602008004469T DE602008004469D1 DE 602008004469 D1 DE602008004469 D1 DE 602008004469D1 DE 602008004469 T DE602008004469 T DE 602008004469T DE 602008004469 T DE602008004469 T DE 602008004469T DE 602008004469 D1 DE602008004469 D1 DE 602008004469D1
Authority
DE
Germany
Prior art keywords
treatment
combination
inflammatory diseases
solvate
pharmaceutically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602008004469T
Other languages
English (en)
Inventor
Johan Raud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardoz AB
Original Assignee
Cardoz AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardoz AB filed Critical Cardoz AB
Publication of DE602008004469D1 publication Critical patent/DE602008004469D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
DE602008004469T 2007-03-30 2008-03-31 Kombination zur verwendung bei der behandlung von entzündlichen erkrankungen Active DE602008004469D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92059607P 2007-03-30 2007-03-30
PCT/GB2008/001142 WO2008119988A1 (en) 2007-03-30 2008-03-31 New combination for use in the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
DE602008004469D1 true DE602008004469D1 (de) 2011-02-24

Family

ID=38328309

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602008004469T Active DE602008004469D1 (de) 2007-03-30 2008-03-31 Kombination zur verwendung bei der behandlung von entzündlichen erkrankungen

Country Status (16)

Country Link
US (1) US20100056552A1 (de)
EP (1) EP2129368B1 (de)
JP (1) JP2010523486A (de)
KR (1) KR20090125077A (de)
CN (1) CN101668521A (de)
AT (1) ATE494892T1 (de)
AU (1) AU2008234667A1 (de)
BR (1) BRPI0809302A2 (de)
CA (1) CA2682572A1 (de)
DE (1) DE602008004469D1 (de)
EA (1) EA200901327A1 (de)
ES (1) ES2385940T3 (de)
IL (1) IL201168A0 (de)
MX (1) MX2009010477A (de)
WO (1) WO2008119988A1 (de)
ZA (1) ZA200906188B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2505196A4 (de) * 2009-11-27 2013-05-01 Univ Tokai Educational System Antithrombosemittel
CN111032021A (zh) * 2017-08-29 2020-04-17 康瑞格制药公司 包含甲磺司特的组合物
JP7399949B2 (ja) * 2018-07-06 2023-12-18 アルジャーノン・ファーマスーティカルズ・インコーポレイテッド 非アルコール性脂肪性肝炎治療のための組成物及び方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU737078C (en) * 1996-05-24 2002-05-02 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
US6585995B1 (en) * 1999-09-21 2003-07-01 Hanson Stephen R Methods and compositions for treating platelet-related disorders
JP2001335473A (ja) * 2000-05-31 2001-12-04 Taisho Pharmaceut Co Ltd 鼻閉改善剤
US20050084478A1 (en) * 2000-10-17 2005-04-21 Chih-Ping Liu Combination therapy using interferon-tau
WO2004002530A1 (ja) * 2002-06-26 2004-01-08 Ono Pharmaceutical Co., Ltd. 慢性疾患治療剤
AU2003241836A1 (en) * 2002-10-03 2004-04-23 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
US20060084695A1 (en) * 2004-04-29 2006-04-20 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7202325B2 (en) * 2005-01-14 2007-04-10 Advanced Cardiovascular Systems, Inc. Poly(hydroxyalkanoate-co-ester amides) and agents for use with medical articles
SG175477A1 (en) * 2005-01-31 2011-11-28 Mylan Lab Inc Hydroxylated nebivolol metabolites

Also Published As

Publication number Publication date
CA2682572A1 (en) 2008-10-09
ES2385940T3 (es) 2012-08-03
ATE494892T1 (de) 2011-01-15
IL201168A0 (en) 2010-05-17
MX2009010477A (es) 2009-10-19
ZA200906188B (en) 2010-06-30
CN101668521A (zh) 2010-03-10
EP2129368A1 (de) 2009-12-09
KR20090125077A (ko) 2009-12-03
WO2008119988A1 (en) 2008-10-09
EP2129368B1 (de) 2011-01-12
EA200901327A1 (ru) 2010-02-26
JP2010523486A (ja) 2010-07-15
BRPI0809302A2 (pt) 2014-10-14
AU2008234667A1 (en) 2008-10-09
US20100056552A1 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
ATE471324T1 (de) Triazolophthalazine
NO20081636L (no) FAP - inhibitorer
MX2007008137A (es) Triazoloftalazinas como inhibidores de pde2.
IS7721A (is) Píperidín-pýrídasón og þalasón sem PDE4 hemlar
EA201170051A1 (ru) Гетероциклическое соединение и его применение
CL2008000873A1 (es) Compuestos derivados de pirrolidin amidas; composicion farmaceutica que comprende dichos compuestos; y su uso para tratar trombosis.
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
CR7977A (es) Anilidas de acido trifluorometil-tiofencarboxilico y su uso como fungicidas
ATE548035T1 (de) Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
MX2007011493A (es) Modalidades antiinflamatorias.
UY3725Q (es) Recipiente para alimentos
EA201270630A1 (ru) Гетероциклические сетр ингибиторы
EA201001495A1 (ru) Карналлит-подобные пищевые соли и продукты из них
CY1113916T1 (el) Παραγωγα ετεροαρυλο πυρρολιδινυλο και πιπεριδινυλο κετονης
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
UY34050A (es) Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol- 2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen
CO6251376A2 (es) Triazolilpiridina cetonas herbicidas
MX2009006507A (es) Nueva combinacion para usarse en el tratamiento de trastornos inflamatorios.
ATE543501T1 (de) Kombination von pemirolast und ramatroban zur verwendung bei der behandlung von entzündlichen erkrankungen
ATE494892T1 (de) Kombination zur verwendung bei der behandlung von entzündlichen erkrankungen
NO20080781L (no) GLEPP-inhibitorer i behandlingen av autoimmune og/eller inflammatoriske sykdommer
NO20091140L (no) Fremgangsmate for fremstilling av polyester nanokompositter
DE502007006880D1 (de) Verwendung von gallium (iii) komplexen zur behandlung von melanomen

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: VONNEMANN, KLOIBER & KOLLEGEN, 20099 HAMBURG